HK1091126A1 - Methods for inhibiting viral replication in vivo - Google Patents
Methods for inhibiting viral replication in vivoInfo
- Publication number
- HK1091126A1 HK1091126A1 HK06111766.3A HK06111766A HK1091126A1 HK 1091126 A1 HK1091126 A1 HK 1091126A1 HK 06111766 A HK06111766 A HK 06111766A HK 1091126 A1 HK1091126 A1 HK 1091126A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- vivo
- methods
- viral replication
- inhibiting viral
- inhibiting
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/18—Testing for antimicrobial activity of a material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/978—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Communicable Diseases (AREA)
- Analytical Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US42749702P | 2002-11-18 | 2002-11-18 | |
PCT/US2003/030770 WO2004046309A2 (en) | 2002-11-18 | 2003-09-29 | Methods for inhibiting viral replication in vivo |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1091126A1 true HK1091126A1 (en) | 2007-01-12 |
Family
ID=32326546
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK06111766.3A HK1091126A1 (en) | 2002-11-18 | 2006-10-25 | Methods for inhibiting viral replication in vivo |
Country Status (9)
Country | Link |
---|---|
US (2) | US7204980B2 (xx) |
EP (1) | EP1599217B1 (xx) |
JP (1) | JP4733393B2 (xx) |
CN (1) | CN1809378B (xx) |
AU (1) | AU2003282883B2 (xx) |
CA (1) | CA2506244C (xx) |
ES (1) | ES2477118T3 (xx) |
HK (1) | HK1091126A1 (xx) |
WO (1) | WO2004046309A2 (xx) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006015512A1 (fr) * | 2004-08-11 | 2006-02-16 | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Arginine déiminase modifiée |
TWI457136B (zh) | 2005-04-04 | 2014-10-21 | Tibotec Pharm Ltd | Hiv-感染之預防 |
FR2884717B1 (fr) * | 2005-04-25 | 2009-07-03 | Erytech Pharma Soc Par Actions | Erythrocytes renfermant de l'arginine deiminase |
CA2606565C (en) | 2005-05-27 | 2016-05-10 | The University Of North Carolina At Chapel Hill | Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications |
RU2008109649A (ru) * | 2005-08-15 | 2009-09-27 | Ф.Хоффманн-Ля Рош Аг (Ch) | ПЭГ-IFNα И РИБАВИРИН ДЛЯ ЛЕЧЕНИЯ ВИРУСА ГЕПАТИТА В |
CN101002945B (zh) * | 2006-01-20 | 2012-09-05 | 清华大学 | 一种用于肿瘤治疗的新型复合物 |
WO2009034055A1 (en) * | 2007-09-10 | 2009-03-19 | Novartis Forschungsstiftung, Zweigniederlassung | Method for predicting the response of a subject suffering from a viral infection of the liver to an antiviral therapy |
US20100222289A1 (en) * | 2007-10-22 | 2010-09-02 | Cfs Research Llc | Methods for diagnosis and treatment of chronic fatigue syndrome |
BR112012003804B1 (pt) | 2009-08-21 | 2019-02-19 | Novan, Inc. | Curativo para ferimentos, método para formar um curativo para ferimentos, e, kit de curativo para ferimento |
ES2958410T3 (es) | 2009-08-21 | 2024-02-08 | Novan Inc | Geles tópicos |
US8591876B2 (en) | 2010-12-15 | 2013-11-26 | Novan, Inc. | Methods of decreasing sebum production in the skin |
WO2012118829A2 (en) | 2011-02-28 | 2012-09-07 | Novan, Inc. | Tertiary s-nitrosothiol-modified nitricoxide-releasing xerogels and methods of using the same |
EP3782653A1 (en) * | 2012-04-04 | 2021-02-24 | Polaris Group | Composition comprising pegylated arginine deiminase |
CA2901795C (en) | 2013-03-15 | 2022-08-02 | Polaris Group | Arginine deiminase with reduced cross-reactivity toward adi - peg 20 antibodies for cancer treatment |
US10463721B2 (en) | 2014-03-18 | 2019-11-05 | Tdw Group | Engineered chimeric pegylated ADI and methods of use |
ES2915382T3 (es) | 2014-09-16 | 2022-06-22 | Polaris Group | Arginina desiminasa con reactividad cruzada reducida hacia anticuerpos ADI - PEG 20 para el tratamiento del cáncer |
WO2016063134A1 (en) | 2014-10-24 | 2016-04-28 | Redhill Biopharma Ltd. | Therapy for inhibition of single-stranded rna virus replication |
US20180296652A1 (en) * | 2016-11-02 | 2018-10-18 | Polaris Group | Formulations of pegylated arginine deiminase |
CN106591271B (zh) * | 2017-03-02 | 2019-07-16 | 江南大学 | 一株酶活和温度稳定性提高的精氨酸脱亚胺酶突变体及其应用 |
IT201700034630A1 (it) * | 2017-03-29 | 2018-09-29 | Univ Degli Studi Di Torino | Pad2 per uso nella prevenzione e/o trattamento o diagnosi di infezioni da virus della famiglia herpesviridae |
CN108324951B (zh) * | 2018-04-16 | 2021-05-25 | 薛剑峰 | 一种精氨酸脱亚胺酶注射剂及其制备方法 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) * | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4609546A (en) * | 1982-06-24 | 1986-09-02 | Japan Chemical Research Co., Ltd. | Long-acting composition |
US5447722A (en) * | 1983-12-12 | 1995-09-05 | University Of Manitoba | Method for the suppression of an immune response with antigen-MPEG conjugates in nonsensitized individuals |
US5080891A (en) * | 1987-08-03 | 1992-01-14 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
JPH0253490A (ja) | 1988-08-16 | 1990-02-22 | Agency Of Ind Science & Technol | アルギニン・デイミナーゼ遺伝子 |
WO1990005534A1 (en) | 1988-11-23 | 1990-05-31 | Genentech, Inc. | Polypeptide derivatives |
JP2900279B2 (ja) | 1989-08-02 | 1999-06-02 | 株式会社ジャパンエナジー | 新規なアルギニンデイミナーゼ、その製造法及び該酵素を有効成分とする制癌剤 |
JP3209338B2 (ja) | 1990-09-10 | 2001-09-17 | 株式会社ジャパンエナジー | ポリエチレングリコール修飾アルギニンデイミナーゼおよびその製造法 |
US5372942A (en) * | 1992-02-10 | 1994-12-13 | Coriell Institute For Medical Research | Protease K resistant arginine deiminase, its method of preparation and its use as an anti-neoplastic agent |
WO1994005332A2 (en) | 1992-09-01 | 1994-03-17 | Berlex Laboratories, Inc. | Glycolation of glycosylated macromolecules |
JP3210457B2 (ja) * | 1992-12-14 | 2001-09-17 | ダウ・コ−ニング・コ−ポレ−ション | 酸化ケイ素膜の形成方法 |
US5477929A (en) * | 1993-12-29 | 1995-12-26 | Malco Products, Inc. | Garden tool |
US5695760A (en) | 1995-04-24 | 1997-12-09 | Boehringer Inglehiem Pharmaceuticals, Inc. | Modified anti-ICAM-1 antibodies and their use in the treatment of inflammation |
US5804183A (en) * | 1997-01-31 | 1998-09-08 | Enzon, Inc. | Arginine deminase derived from mycoplasma arthritidis and polymer conjugates containing the same |
US6635462B1 (en) * | 1997-05-12 | 2003-10-21 | Phoenix Pharmacologies, Inc. | Mutated form of arginine deiminase |
US6183738B1 (en) * | 1997-05-12 | 2001-02-06 | Phoenix Pharamacologics, Inc. | Modified arginine deiminase |
IT1298918B1 (it) * | 1998-02-20 | 2000-02-07 | Mendes Srl | Uso di batteri dotati di arginina deiminasi per indurre apoptosi e/o ridurre una reazione infiammatoria e composizioni farmaceutiche |
US6258831B1 (en) * | 1999-03-31 | 2001-07-10 | The Procter & Gamble Company | Viral treatment |
JP2004515232A (ja) * | 2000-11-28 | 2004-05-27 | フエニツクス・フアーマコロジクス・インコーポレーテツド | 修飾されたアルギニンデイミナーゼ |
-
2003
- 2003-09-29 CN CN038252643A patent/CN1809378B/zh not_active Expired - Fee Related
- 2003-09-29 AU AU2003282883A patent/AU2003282883B2/en not_active Ceased
- 2003-09-29 US US10/674,666 patent/US7204980B2/en not_active Expired - Lifetime
- 2003-09-29 EP EP03774504.9A patent/EP1599217B1/en not_active Expired - Lifetime
- 2003-09-29 JP JP2004553429A patent/JP4733393B2/ja not_active Expired - Fee Related
- 2003-09-29 CA CA2506244A patent/CA2506244C/en not_active Expired - Fee Related
- 2003-09-29 ES ES03774504.9T patent/ES2477118T3/es not_active Expired - Lifetime
- 2003-09-29 WO PCT/US2003/030770 patent/WO2004046309A2/en active Search and Examination
-
2006
- 2006-10-25 HK HK06111766.3A patent/HK1091126A1/xx not_active IP Right Cessation
-
2007
- 2007-03-21 US US11/689,166 patent/US20070172469A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
ES2477118T3 (es) | 2014-07-15 |
US20040131604A1 (en) | 2004-07-08 |
US20070172469A1 (en) | 2007-07-26 |
CN1809378B (zh) | 2010-06-23 |
JP4733393B2 (ja) | 2011-07-27 |
WO2004046309A2 (en) | 2004-06-03 |
AU2003282883A1 (en) | 2004-06-15 |
WO2004046309A3 (en) | 2005-08-04 |
AU2003282883B2 (en) | 2008-12-04 |
JP2006515281A (ja) | 2006-05-25 |
CA2506244A1 (en) | 2004-06-03 |
EP1599217B1 (en) | 2014-04-16 |
CN1809378A (zh) | 2006-07-26 |
CA2506244C (en) | 2012-10-30 |
EP1599217A2 (en) | 2005-11-30 |
US7204980B2 (en) | 2007-04-17 |
EP1599217A4 (en) | 2006-11-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1091126A1 (en) | Methods for inhibiting viral replication in vivo | |
IL174131A0 (en) | Improvements in vaccination | |
IL169562A (en) | A method to improve the in vitro stability of purified alpha galactosidase a | |
PT1583542E (pt) | Composições e métodos para terapia de combinação antiviral | |
EP1542717A4 (en) | IMPROVEMENT RELATING TO VACCINES OR RELATED THERETO | |
EP1638977A4 (en) | SALINOSPORAMIDES AND METHODS OF USE | |
AU2003234336A8 (en) | Methods and compositions for use in preparing sirnas | |
GB0206461D0 (en) | Improvements in vaccination | |
GB0409107D0 (en) | Investment system | |
HK1079984A1 (zh) | 抑制hiv複製的甘氨酰胺衍生物 | |
AU2003213586A8 (en) | Booklet maker | |
HK1102395A1 (en) | Indene derivatives and process for the preparation thereof | |
GB0417263D0 (en) | Process and system | |
IL183702A0 (en) | Difluoronucleosides and process for preparation thereof | |
GB2384704B (en) | Improvements in spatulas | |
EP1756036A4 (en) | INDENED DERIVATIVES AND PROCESS FOR THEIR PREPARATION | |
ZA200600473B (en) | Salinosporamides and methods for use thereof | |
AU2003288699A8 (en) | Method for in vivo sensing | |
GB0217064D0 (en) | Improvements in tranquilliser darts | |
GB0327133D0 (en) | Viral replication | |
GB0327270D0 (en) | Viral replication | |
GB0214032D0 (en) | Replication technology | |
GB0207693D0 (en) | Replication method | |
GB2402163B (en) | Improvements in safety means | |
IL177194A0 (en) | Flat system for using in the oral cavity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20191003 |